Drug Approval | April 14, 2026
CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
The campaign builds on the three-year partnership unveiled earlier this season
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The event also featured discussions on emerging trends in joint replacement surgery
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
Subscribe To Our Newsletter & Stay Updated
